title: Treatment of Non-Alcoholic Fatty Liver Disease.
abstract: Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions from steatosis to cirrhosis and hepatocellular carcinoma. Steatosis is a benign reversible condition, which does not need treatment. Cirrhosis and hepatocellular carcinoma are the end stages of any chronic liver disease and do not have etiology-specific treatments. In this chapter, we will review treatment options for non-alcoholic steatohepatitis, which is the progressive form of NAFLD. Basically there are 2 strategies, the first of which is to address lifestyle and the second to use medication. The first approach is the most physiologic, the least expensive, but is also the most difficult to implement. The second approach, which should help patients who failed the first approach, is at the advanced clinical research stage.
authors.affiliation: Department of Clinical Research, Hepatology, Inselspital, University of Bern, Bern, Switzerland.
authors.forename: Antonia
authors.initials: A
authors.lastname: Scherer
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Dufour
mesh_terms: D000975:Antioxidants / Q000627:therapeutic use; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D008019:Life Style; D008099:Liver / Q000187:drug effects; D058990:Molecular Targeted Therapy; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy / Q000628:therapy*
chemical_list: D000975:Antioxidants; D015507:Drugs, Investigational; C464660:obeticholic acid; D002635:Chenodeoxycholic Acid